***Background.*** Recent pharmacokinetic/pharmacodynamic (PK/PD) evaluations find that higher oseltamivir exposures may reduce duration of viral shedding and symptoms. However, the impact of such findings on pandemic planning decisions and use of stockpiles has not been described. This study explored the economic impact of oseltamivir dose optimization in supporting pandemic influenza planning decisions in the US.

***Methods.*** We simulated the infected population across a 1 year seasonal influenza outbreak using a health economic model linked to a PK/PD-epidemiology model (SEIR). Different scenarios were considered to evaluate the cost-effectiveness of high dose (150mg BID) vs standard dose (75mg BID) oseltamivir, low and high virulence, varying transmissibility (low and high attack rates (37% and 67.5% respectively)) and drug uptake (25%, 50%, and 80%). The analysis was conducted from a societal perspective, incorporating both direct and indirect costs. Disease epidemiology and costs were US-specific. Sensitivity analyses were performed to test model robustness.

***Results.*** Results for incremental cost, deaths averted, quality-adjusted life-years (QALY) gained, and incremental cost-effectiveness ratios (ICERs) for high dose compared with standard dose oseltamivir under different scenarios are given in the table.

  Comparators (150 mg vs 75 mg)   Incremental cost (USD)^3^   Death averted   QALY gained   ICER(per QALY)
  ------------------------------- --------------------------- --------------- ------------- ----------------
  High virulence^1^                                                                         
  high transmissibility                                                                     
  25%^2^                          -21,935,208                 148.4           149.1         -147,108
  50%^2^                          -31,673,695                 227             227.2         -139,384
  80%^2^                          -21,126,363                 190             189.4         -111,573
  low transmissibility                                                                      
  25%^2^                          -4,212,570                  44.3            44.5          -94,729
  50%^2^                          4,335,233                   13.7            13.7          317,341
  80%^2^                          9,116,920                   9               9             1,015,910
  Low virulence                                                                             
  high transmissibility                                                                     
  25%^2^                          -14,661,284                 74.5            77.2          -190,011
  50%^2^                          -20,562,861                 114             117.2         -175,496
  80%^2^                          -11,842,304                 95.4            97.2          -121,822
  low transmissibility                                                                      
  25%^2^                          -2,043,215                  22.2            23            -88,790
  50%^2^                          5,003,199                   6.9             7             710,268
  80%^2^                          9,556,934                   4.5             4.6           2,074,257

^1^ Proportion of infected cases who visited ED was assumed to be twice as high as in low severity scenario ^2^ Uptake ^3^negative signs mean cost-saving

***Conclusion:*** These results suggest the potential for high dose oseltamivir to provide economic value, and may have a role in pandemic influenza particularly in high transmissability scenarios; the role of high dose oseltamivir should be investigated further.
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